Advancements in the Management of R/R AML: ASH 2024 - Episode 7

MRD Testing and the Role of Revumenib in Treatment Response

January 29, 2025

Thomas W. LeBlanc, MD, MA, MHS, FAAHPM, FASCO , James Blachly, MD, Aaron Goldberg, MD, PhD Memorial Sloan Kettering Cancer Center, Rami Komrokji, MD, Gabe Mannis, MD , Michael J. Thirman, MD

Panelists discuss the role of minimal residual disease (MRD) testing in acute monocytic leukemia (AML), key findings from the Australasian Leukaemia and Lymphoma Group (ALLG) AMLM26 INTERCEPT study on revumenib, and how the efficacy of revumenib in achieving MRD negativity in NPM1-mutated AML informs future MRD-guided treatment strategies, including the potential integration of menin inhibitors into standard AML relapse prevention protocols.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Treatment Strategies for Relapsed/Refractory AML Patients

EP. 2: Treatment Goals and Unmet Needs in R/R AML

EP. 3: Navigating Challenges in Second- and Third-Line AML Therapy

EP. 4: Revumenib’s FDA Approval and Clinical Implications

EP. 5: Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia

EP. 6: Adverse Event Management and Patient Safety With Revumenib

Now Viewing

EP. 7: MRD Testing and the Role of Revumenib in Treatment Response

EP. 8: Integrating Revumenib Into Current R/R AML Treatment Paradigms

EP. 9: Genetic Testing and Molecular Profiling in AML

EP. 10: Emerging Combination Strategies and Preclinical Findings

EP. 11: Future Perspectives on Menin Inhibitors in Acute Leukemias

EP. 12: Closing Perspectives on R/R AML Treatment Advances

Video content above is prompted by the following:

Dr. LeBlanc to ask GROUP: What role does MRD testing play within AML?
Dr. LeBlanc to ask Dr. Mannis: Briefly comment on the key findings presented for revumenib from the ALLG AMLM26 INTERCEPT study.(Loo, S, et al. ASH 2024. Oral Abstract 223, Session: 619 or pg. 11)
Dr. LeBlanc to ask Dr. Thirman: How does the efficacy of revumenib in achieving MRD negativity in NPM1-mutated AML inform the future of MRD-guided treatment strategies, and what might this mean for integrating menin inhibitors into standard AML relapse prevention protocols?